Early data from the Phase III CONVOKE study, an investigational digital prescription treatment used as an adjunct to standard antipsychotic treatment for experiential negative symptoms of schizophrenia, is promising. The aim is to provide patients with interactive psychosocial intervention techniques targeting defeatist beliefs and lack of motivation.
Developed by Click Therapeutics, Inc. et Boehringer Ingelheim CT-155 or BI 3972080, code name for the American CONVOKE study, is an experimental digital prescription treatment that aims to provide interactive psychosocial intervention techniques as a complement to standard antipsychotic treatment in people with schizophrenia who present with negative symptoms. Participants included in the phase III study which lasted 16 weeks were aged 18 years and over and suffered from stabilized schizophrenia by a antipsychotic treatment.
CT-155 is designed to combat defeatist beliefs and lack of motivation. It uses a personalized goal-setting method, adapted to each patient’s current level of functioning (adaptive goal setting), to promote engagement in concrete activities (behavioral activation). In addition, the CT-155 offers therapeutic interventions aimed at helping patients achieve their goals (cognitive restructuring, social skills training, positive affect training, development of distress tolerance).
« CT-155, which integrates psychosocial interventions delivered through an adaptive goal-setting technique, is the first investigational psychosocial therapy to demonstrate a reduction in negative symptoms of schizophrenia in a pivotal trial said Emmanuelle Clerisme-Beaty, U.S. Chief Medical Officer and Senior Vice President, Medicine, Boehringer Ingelheim Pharmaceuticals, Inc. In collaboration with Click Therapeutics, we developed CT-155 to address the dual challenges of accessibility and continuity of use of psychosocial therapy for people suffering from negative symptoms of schizophrenia. We look forward to continuing discussions with regulatory authorities in an effort to help patients. »
« The positive results observed in this CONVOKE trial represent a major advance in understanding negative symptoms, a long-standing unmet need in mental health said Dr. Gregory W. Mattingly, clinical associate professor at Washington University in St. Louis, Missouri, principal investigator of the clinical trials for the Midwest Research Group and founding partner of St. Charles Psychiatric Associates. “ This research highlights the importance of integrating innovative approaches in the treatment of schizophrenia. The emergence of prescription digital therapeutics, such as CT-155, if approved, could allow patients to access psychosocial intervention wherever they are.
• Boehringer and Click Therapeutics present pivotal data for investigational prescription digital therapeutic CT-155 showing a statistically significant reduction in negative symptoms of schizophrenia; press release of October 13, 2025 (in English). The results of this phase III study were presented at the 38e annual congress of the European College of Neuropsychopharmacology (ECNP) in Amsterdam.